Also known as: empagliflozin
JARDIANCE (empagliflozin) is an SGLT2 inhibitor used for type 2 diabetes and cardio-renal indications including heart failure, chronic kidney disease, and cardiovascular risk reduction. It lowers glucose by increasing urinary glucose excretion through inhibition of renal glucose reabsorption. The FDA first approved it on August 1, 2014.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
Finerenone met its primary endpoint in reducing albuminuria in type 1 diabetic kidney disease, marking the first successful drug trial in 30 years for this population. Separately, SGLT2 inhibitors showed superior kidney protection compared to GLP-1 medications in type 2 diabetes patients.
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
The Trump administration launched TrumpRx.gov in February 2026, offering discounted prices on dozens of brand-name prescription drugs through negotiated deals with pharmaceutical companies, though critics warn many listed drugs have cheaper generic alternatives.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07035457 |
A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together |
COMPLETED | PHASE1 |
| NCT06527846 |
Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease |
ACTIVE_NOT_RECRUITING | |
| NCT06308679 |
A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions |
NOT_YET_RECRUITING | PHASE1 |
| NCT06287073 |
JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD) |
COMPLETED | |
| NCT05262764 |
Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF) |
COMPLETED | |
| NCT05236673 |
Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure |
COMPLETED | |
| NCT02367131 |
Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus |
COMPLETED |
